NasdaqGS:TEM
NasdaqGS:TEMLife Sciences

Tempus AI (TEM) Is Up 8.5% After FDA Clearance for Advanced Cardiac MRI Mapping – Has the Bull Case Changed?

Tempus AI recently received FDA 510(k) clearance for its updated Tempus Pixel platform, enabling T1 and T2 inline mapping for enhanced cardiac MR image analysis using artificial intelligence. This advancement allows clinicians to generate precise, quantitative tissue assessments directly from raw MRI data, providing new diagnostic capabilities even on scanners without native mapping support. We'll explore how this recent regulatory milestone and Tempus Pixel's expanded functionality could...
NasdaqGS:IBRX
NasdaqGS:IBRXBiotechs

Why ImmunityBio (IBRX) Is Up 8.3% After Promising ANKTIVA Data in Advanced Lung Cancer

ImmunityBio announced new findings from its Phase 2 QUILT-3.055 study, revealing that ANKTIVA reversed lymphopenia and was associated with significantly longer median overall survival in checkpoint inhibitor-resistant advanced non-small cell lung cancer patients, as presented at the IASLC 2025 World Conference on Lung Cancer. These results spotlight ANKTIVA as the first therapy specifically under investigation for reversing cancer-related lymphopenia, targeting an unmet need for patients...